AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01071083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1000 mg intravenous every 4 weeks
Study NCT01071083 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: placebo intravenous every 4 weeks
Study NCT01071083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: 20 mg subcutaneous once daily
Study NCT02469675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: One TMS pulse every 10 seconds for 20 minutes
Study NCT02469675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation
Description: One median nerve pulse every 10 seconds for 20 minutes
Study NCT02469675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical transcutaneous stimulation
Description: One cervical pulse every 10 seconds for 20 minutes
Study NCT01095029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim II - 3058
Description: Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
Study NCT02515981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NH Medicaid Incentives Program
Study NCT00303134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet Cell Transplantation
Description: Islet Cell Transplantation for patients with type 1 diabetes mellitus
Study NCT00665704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics website
Description: Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
Study NCT01855321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
Study NCT01855321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
Study NCT02751255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Description: Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
Study NCT03650179 — intervention group
Intervention type: OTHER
Intervention: Observational study : No intervention
Description: Observational study : No intervention. Only exporting data
Study NCT03029000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbo-filgrastim
Description: solution for subcutaneous injection
Study NCT03667586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy
Description: Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
Study NCT03667586 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group cognitive behavioral therapy
Description: Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
Study NCT00185731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg orally once daily
Study NCT04720885 — intervention group
Intervention type: PROCEDURE
Intervention: kind of surgery
Description: hysteroscopy, curettage, other
Study NCT02232685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-Choline PET/CT
Description: 18F-Choline PET/CT
Study NCT01385501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video intervention along with educational hand out
Description: The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
Study NCT02200614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
Study NCT02200614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 2 tablets twice daily with food.
Study NCT01465074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex
Description: 4 mg
Study NCT01465074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum
Description: 30 min chewing, one dose
Study NCT04252040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS with guided imagery
Description: The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
Study NCT01287585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
Description: 18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
Study NCT01287585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly, intramuscular, until disease progression or toxicity.
Study NCT01287585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: treatment of disease-related symptoms throughout the study.
Study NCT01287585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: treatment of disease-related symptoms throughout the study.
Study NCT04010565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
Study NCT04526028 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant Injectable Product
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Study NCT04526028 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
Study NCT01465412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preladenant
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
Study NCT01465412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
Study NCT02257346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
Study NCT02257346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
Study NCT02817763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft (CTG)
Description: Periodontal surgical technique to treat gingival recessions
Study NCT02817763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG plus resin composite restoration
Description: Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
Study NCT02817763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium dipyrone
Description: sodium dipyrone was recommended for all participants after the surgical procedures.
Study NCT02817763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium dipyrone
Description: sodium dipyrone was recommended for all participants after the surgical procedures.
Study NCT02701465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise: local high intensity interval exercise
Description: The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
Study NCT02701465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise: best clinical practice
Description: The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Pill
Description: Ketoconazole pill is taken 4 times per Inpatient Stay
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix subcutaneous injection is administered twice per Inpatient Stay
Study NCT03196921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encochleated Amphotericin B
Description: lipid-crystal nanoparticle formulation of amphotericin B; oral
Study NCT00687258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitabranE ViE
Description: Polysulfone dialyser with vitamin E alpha-tocopherol
Study NCT02688634 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
Study NCT03120975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized decision support and audit & feedback
Description: * suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication
Study NCT03120975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit & Feedback
Description: \* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
Study NCT03120975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard antibiotic stewardship
Description: * Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)
Study NCT03120975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic stewardship
Description: * Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)
Study NCT03219528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 mg three times daily for 14 days
Study NCT03219528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: Low FODMAP dietary intervention for 4 weeks
Study NCT01354821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular aortic repair
Description: Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
Study NCT01354821 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open surgical repair
Description: Conventional therapy in France with the national database of the M.O.H.
Study NCT05917730 — intervention group
Intervention type: BEHAVIORAL
Intervention: Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)
Description: Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell.
Study NCT01754714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 1000 mg
Description: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
Study NCT01094574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
Study NCT01094574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
Study NCT01094574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
Study NCT00134680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg by mouth daily
Study NCT00134680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
Study NCT01731119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latuda©
Description: All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Pills is taken twice per Inpatient Stay
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Injection
Description: Dexamethasone IV injection is given twice per Inpatient Stay
Study NCT01754714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 1500 mg
Description: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
Study NCT02600936 — intervention group
Intervention type: DEVICE
Intervention: vein stent placement
Description: Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
Study NCT03481972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline and tauroursodeoxycholic acid
Description: doxycicline and tauroursodeoxycholic acid
Study NCT03481972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT02885220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Program
Description: No scheduled intermediate weight loss goals provided to patient
Study NCT02885220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed Program
Description: Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
Study NCT01825473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Study NCT01825473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel intra-luminal impedance (MII) pH monitoring
Study NCT01825473 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multi-channel intra-luminal impedance (MII) pH monitoring
Study NCT01825473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (D5W)
Study NCT03033992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
Description: The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
Study NCT03033992 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent Optune and RT followed by Optune System alone
Description: In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
Study NCT02632266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Powder HMF
Description: powder human milk fortifier
Study NCT02632266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid HMF
Description: Liquid human milk fortifier
Study NCT03828721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rx for Success Smartphone Application
Description: The Rx for Success (RS) mobile application (app) was developed by the non-profit, Children, Inc. The app is designed to be informational and motivational with both video and cueing content. The app uses a View It, Cue It, Do It model that allows parents to quickly download the smartphone app, view brief videos of age-indexed, research-based language enrichment practices; and regulate a push notification cueing program. Videos embedded in the RS app provide a summary of dialogic reading tailored for the child's age, and suggestions for encouraging verbal interactivity and social-emotional engagement through dialogic reading. Key behaviors reinforced by the app include discussing the story before reading to build interest and enthusiasm, followed by interactive reading modeled by specific types of verbal/behavioral prompts for the parent to make and responses to what the child says or does.
Study NCT03828721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - screen time reduction
Description: Control families will receive a new, specially designed children's book regarding limiting screen-based media use and encouraging healthy/active alternatives (Baby Unplugged: Play, Hutton/Jones, blue manatee press), which lists American Academy of Pediatrics screen time recommendations on the back cover.
Study NCT01754714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 2000 mg
Description: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
Study NCT03549689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
Description: Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.